Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients

被引：0
|
作者：
Baudens, Guy
Coquerelle, Pascal [1 ]
Guyot, Marie-Helene [2 ]
Loiseau-Peres, Sylvie [3 ]
Marguerie, Laurent [4 ]
Maury, Frederic
Eric, Viellard
Letarouilly, Jean-Guillaume [5 ]
Salmon, Jean-Hugues [6 ]
Flipo, Rene-Marc [5 ]
Gervais, Elisabeth [7 ]
机构：
[1] Bethune Hosp, Rheumatol, Bethune, France
[2] Roubaix Hosp, Rheumatol, Roubaix, France
[3] Orleans Hosp, Rheumatol, Orleans, France
[4] Calot Inst, Rheumatol, Berck Sur Mer, Berck Sur Mer, France
[5] Roger Salengro Univ Hosp, Lille, France
[6] Reims Univ Hosp, Rheumatol, Reims, France
[7] CHU Poitiers, Rheumatol, Poitiers, France
来源：
ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1495
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SWITCHING RATE OF ANTI-TNF AGENTS IN SPONDYLOARTHRITIS PATIENTS: TREASURE - REAL LIFE DATA
    Kalyoncu, Umut
    Kiraz, Sedat
    Erden, Abdulsamet
    Kucuksahin, Orhan
    Kasifoglu, Timucin
    Dalkilic, Ediz
    Bes, Cemal
    Kanitez, Nilufer Alpay
    Emmungil, Hakan
    Atagunduz, Pamir
    Coskun, Belkis Nihan
    Yagiz, Burcu
    Koca, Suleyman Serdar
    Cinar, Muhammet
    Ates, Askin
    Akar, Servet
    Gercik, Onay
    Ersozlu, Duygu
    Yazisiz, Veli
    Kimyon, Gezmis
    Aydin, Muge
    Mercan, Ridvan
    Oz, Burak
    Bilge, Nazife Sule Yasar
    Akar, Zeynel Abidin
    Karadag, Omer
    Dincer, Ayse Bahar Kelesoglu
    Yilmaz, Sedat
    Ilgen, Ufuk
    Pehlivan, Yavuz
    Terzioglu, Ender
    Kilic, Levent
    Erten, Sukran
    Ertenli, Ali Ihsan
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 882 - 883
  • [2] ANTI-TNF ALPHA DRUGS RETENTION RATE AT ANKYLOSING SPONDYLITIS AND AXIAL SPONDYLOARTHRITIS: HUR-BIO REAL LIFE RESULTS
    Kalyoncu, U.
    Babaoglu, H.
    Erden, A.
    Kilic, L.
    Torgutalp, M.
    Karadag, O.
    Kilickap, S.
    Akdogan, A.
    Bilgen, S. A.
    Ertenli, I.
    Kiraz, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 279 - 280
  • [3] Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohort
    Verstockt, B.
    Vieujean, S.
    Truyens, M.
    Julsgaard, M.
    Pugliese, D.
    Aslan, D.
    Prokopic, M.
    Lim, S.
    Vigano, C.
    Festa, S.
    Ramos, L.
    Garcia, M. J.
    Plaza, R.
    Noviello, D.
    Savarino, E.
    Drobne, D.
    Imperatore, N.
    Ribaldone, D. G.
    Van Dongen, J.
    Teich, N.
    Wahed, M.
    Barberio, B.
    Goren, I.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 805 - 805
  • [4] SECUKINUMAB IS FREQUENTLY PREFERRED IN MULTI ANTI-TNF RESISTANCE SPONDYLOARTHRITIS PATIENTS: HUR-BIO REAL LIFE RESULTS
    Armagan, B.
    Kilic, L.
    Yardimci, G. K.
    Bilgin, E.
    Farisogullari, B.
    Bolek, E. C.
    Duran, E.
    Karadag, O.
    Akdogan, A.
    Bilgen, S. A.
    Ertenli, A. I.
    Kalyoncu, U.
    Kiraz, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 419 - 420
  • [5] ASAS PARTIAL REMISSION RATIO OF AS AND AXIAL SPONDYLOARTHRITIS PATIENTS DURING ANTI-TNF TREATMENTS: HUR-BIO REAL LIFE RESULTS
    Kalyoncu, U.
    Kilic, L.
    Erden, A.
    Seyhoglu, E.
    Kilickap, S.
    Sener, Y. Z.
    Aktas, B. Y.
    Guven, D.
    Karadag, O.
    Akdogan, A.
    Bilgen, S. A.
    Ertenli, I.
    Kiraz, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 278 - 278
  • [6] Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study
    Hupe, M.
    Streichenberger, A.
    Wils, P.
    Arab, N.
    Serrero, M.
    Amiot, A.
    Bozon, A.
    Vuitton, L.
    Fumery, M.
    Altwegg, R.
    Nachury, M.
    Hebuterne, X.
    Yzet, C.
    Coban, D.
    Dodel, M.
    Bazoge, M.
    Pereira, B.
    Buisson, A.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1312 - 1318
  • [7] IMPROVEMENT OF FATIGUE IN PATIENTS WITH SPONDYLOARTHRITIS TREATED WITH ANTI-TNF THERAPY: A PROSPECTIVE STUDY IN A REAL-LIFE SETTING
    Desouches, S.
    Gaigneux, E.
    Louati, K.
    Lemeunier, L.
    Beauvais, C.
    Sellam, J.
    Berenbaum, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1299 - 1299
  • [8] Better Retention Rate at 5 Years of Anti-TNF Agents Used in Conjunction with Methotrexate Versus Anti-TNF Monotherapy in Patients with Rheumatoid Arthritis: Real-Life Data from the Rhumadata Computerized Database
    Choquette, Denis
    Sauvageau, Diane
    Haraoui, Boulos
    Raynauld, Jean-Pierre
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 994 - 995
  • [9] Better Retention Rate of Rituximab Vs Anti-Tnf Agents As Second Line therapy in RA Patients Failing a First Anti-Tnf Agents: Results From the Rhumadata® Registry
    Choquette, D.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S859 - S859
  • [10] Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India
    Sahu, Pabitra
    Vuyyuru, Sudheer K.
    Kante, Bhaskar
    Agarwal, Ashish
    Sharma, Raju
    Das, Prasenjit
    Panwar, Rajesh
    Jain, Saransh
    Bopanna, Sawan
    Makharia, Govind
    Kedia, Saurabh
    Ahuja, Vineet
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2020, 39 (04) : 388 - 397
12345